Pharvaris N.V. (PHVS) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Leiden, Netherlands. The current CEO is Berndt Axel Edvard Modig.
PHVS has IPO date of 2021-02-05, 108 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $1.88B.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
